J Neurogastroenterol Motil 2015; 21(3): 330-336  https://doi.org/10.5056/jnm15094
Prokinetics in the Management of Functional Gastrointestinal Disorders
Eamonn M M Quigley
Division of Gastroenterology and Hepatology, Department of Medicine, Houston Methodist Hospital, Houston, Texas, USA
Correspondence to: Eamonn M M Quigley, MD, FRCP, FACP, FACG, FRCPI, Division of Gastroenterology and Hepatology, Houston Methodist Hospital, 6550 Fannin St, SM 1001, Houston, Texas 77030, USA, Tel: +1-713-441-0853, Fax: +1-713-797-9595, E-mail: equigley@tmhs.org
Received: June 1, 2015; Accepted: June 23, 2015; Published online: July 3, 2015.
© The Korean Society of Neurogastroenterology and Motility. All rights reserved.

cc This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

A variety of common and some not common gastrointestinal syndromes are thought to be based on impaired gut motility. For some, the role of motility is well defined, for others and the functional gastrointestinal disorders, in particular, the role of hypo- or dysmotility remains unclear. Over the years pharmacological and physiological laboratories have developed drugs which stimulate gut motility; many have been evaluated in motility and functional disorders with what can best be described as mixed results. Lack of receptor specificity and resultant expected and unexpected adverse events have led to the demise of some of these agents. Newer, more selective agents offer promise but the heterogeneity of the clinical disorders they target continues to pose a formidable challenge to drug development in this area.

Keywords: Constipation, Dyspepsia, Gastroparesis, Intestinal pseudo-obstruction, Irritable bowel syndrome

This Article



Aims and Scope